Skip to content

Clinical trials

Precursor Cell Lymphoblastic Leukemia-Lymphoma trials in Italy with unknown status

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Precursor Cell Lymphoblastic Leukemia-Lymphoma Status: Unknown status Country / region: Italy Clear all

21 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20061
20071
20081
20092
20121
20141
20171
20181
20191
20203
20213
20231
20241

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status21

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Gruppo Italiano Malattie EMatologiche dell'Adulto3
University of Bologna3
Gilead Sciences2
IRCCS Burlo Garofolo2
IRCCS SYNLAB SDN2
Bambino Gesù Hospital and Research Institute1
European Organisation for Research and Treatment of Cancer - EORTC1
Fondazione Italiana Linfomi - ETS1
Fondazione Matilde Tettamanti Menotti De Marchi Onlus1
National Cancer Institute, Naples1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma21
Lymphoma4
Lymphoma, Non-Hodgkin4
Burkitt Lymphoma3
Leukemia, Lymphocytic, Chronic, B-Cell3
Lymphoma, B-Cell, Marginal Zone3
Lymphoma, Follicular3
Lymphoma, Large B-Cell, Diffuse3
Lymphoma, Large-Cell, Immunoblastic3
Lymphoma, Mantle-Cell3

Trials

Showing 1 to 21 of 21. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.